Covid-19 roundup: Catal­ent lends vac­cine pro­duc­tion ca­pac­i­ty to As­traZeneca/Ox­ford for hun­dreds of mil­lions dos­es

5 years ago
Financing
Coronavirus

Eli Lil­ly launch­es PhI­II JAK study, aim­ing for the first drug to low­er mor­tal­i­ty in Covid-19

5 years ago
R&D
Coronavirus

Mo­men­ta clears a PhII hur­dle on nipo — but one big ri­val re­mains well in the lead in this packed field

5 years ago
R&D

Sure, Bit Bio got some sig­nif­i­cant cash for its cell cod­ing work. But it’s the in­sid­ers who are back­ing them that ...

5 years ago
Financing
R&D

Sino­vac posts pos­i­tive PhI/II da­ta for their Covid-19 vac­cine as re­searchers rush in­to a piv­otal test

5 years ago
R&D
Coronavirus

UCB flash­es the da­ta be­hind its pos­i­tive pso­ri­a­sis read­outs. Can it com­pete in a crowd­ed field?

5 years ago
R&D

'Ris­ing star' CEO re­counts path from pre-med to break­through meds; Den­dreon taps Big Phar­ma vet Ja­son O'Neill as CEO

5 years ago
Peer Review

Sanofi and Re­gen­eron out­line Dupix­ent plans; In­dus­try lob­by­ing brings £30 mil­lion for UK's Bio­med­ical Cat­a­lyst

5 years ago
News Briefing

Can­cer drug­mak­er Agios of­fers promis­ing da­ta from two stud­ies test­ing blood dis­or­der drug

5 years ago
Deals
R&D

The pan­dem­ic IPOs keep rolling, as Gen­er­a­tion, Avid­i­ty, Vax­cyte each claim 200M+

5 years ago
Financing

Mod­er­na bur­nish­es its PhI­II-ready Covid-19 vac­cine with promis­ing mouse da­ta — which sug­gest one dose might be ...

5 years ago
R&D
Coronavirus

Covid-19 roundup: Chi­na's Sino­vac goes to Brazil for PhI­II; As­traZeneca signs Emer­gent on for $87M man­u­fac­tur­ing deal

5 years ago
Coronavirus

FDA weighs post-pan­dem­ic chal­lenges at BIO meet­ing

5 years ago
FDA+
Coronavirus

Lenti­Glo­bin con­tin­ues to de­liv­er in lat­est sick­le cell up­date as blue­bird out­lines path to ac­cel­er­at­ed ap­proval, ...

5 years ago
R&D
Cell/Gene Tx

Apel­lis coun­ters Alex­ion’s cri­tique, clears up FDA ques­tions as block­buster de­ci­sion looms

5 years ago
R&D
FDA+

As­traZeneca spin­off scores maid­en FDA ap­proval, where it will field Alex­ion com­pe­ti­tion and an im­mi­nent Roche ri­val

5 years ago
R&D
Pharma

Ver­tex and CRISPR spot­light an­oth­er im­por­tant gene edit­ing ad­vance in a march to a hoped-for cure

5 years ago
R&D
Cell/Gene Tx

Two pre­clin­i­cal biotechs rid­ing the IPO wave this week look to raise $466M-plus; Black­stone's Galakatos backs Rea­ta ...

5 years ago
News Briefing

Take­da con­tin­ues post-Shire sell­off, inch­ing clos­er to $10B goal

5 years ago
Deals

It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

5 years ago
Deals
R&D

Fu­eled with a fresh cash in­jec­tion, Cul­li­nan ex­pands its pipeline with a bid to de­vel­op a new com­bi­na­tion drug for ...

5 years ago
R&D

Mod­er­na floors it in­to PhI­II with their Covid-19 vac­cine, plan­ning quick start with a thumbs-up from FDA on tri­al ...

5 years ago
R&D
Coronavirus

At­tor­neys gen­er­al bring an­oth­er ‘col­lu­sion’ case against gener­ic mak­ers, nam­ing No­var­tis and Pfiz­er among over a ...

5 years ago
Pharma

Covid-19 roundup: Re­gen­eron puts its an­ti­bod­ies in­to the clin­ic, rac­ing with Eli Lil­ly for fall au­tho­riza­tion

5 years ago
Coronavirus
First page Previous page 819820821822823824825 Next page Last page
A service from the Financial Times